Clinical trials: Triple-negative Metastatic Breast Cancer
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Metastatic Triple-Negative Breast Cancer
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first…
- Trial name
- NCT07011654
- Testing
- Sacituzumab govitecan, Naxitamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Metastasis
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
- Trial name
- NCT00371254
- Testing
- Dasatinib
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Bristol-Myers Squibb
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast cancer that has come back (recurrent) or has…
- Conditions
- Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02595905
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Veliparib
- Where
- 810 sites in United States, Puerto Rico
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
Triple -Negative Breast Cancer, Estrogen Receptor Negative
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
This pilot trial studies how well chemokine modulation therapy works when given prior to pembrolizumab in treating participants with triple-negative breast cancer that has spread to other places in the body.
- Conditions
- Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC
- Trial name
- NCT03599453
- Testing
- Biopsy, Chemokine Modulation Therapy, Celecoxib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Breast Cancer
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated metastatic triple-negative breast cancer.
- Trial name
- NCT01176669
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of veliparib when given together with irinotecan hydrochloride in treating patients with cancer that has spread to other parts of the body or that cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
- Trial name
- NCT00576654
- Testing
- Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Triple Negative Breast Cancer
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule.
- Trial name
- NCT02802423
- Testing
- BLEX 404 Oral Liquid
- Volunteers
- 44 people
- Sponsor
- BioLite, Inc.
Breast Cancer, Breast Cancer Female
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain.
- Conditions
- Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer
- Trial name
- NCT06176261
- Testing
- Datopotamab Deruxtecan
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Nancy Lin, MD
Triple Negative Breast Cancer
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast…
- Trial name
- DIAMOND (NCT06954480)
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Durvalumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Queen Mary University of London
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Triple Negative Breast Neoplasms
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
- Trial name
- ABBICAR (NCT06365788)
- Testing
- Abemaciclib, Bicalutamide
- Where
- 6 sites in Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
METASTATIC BREAST CANCER
Ixabepilone and SBRT For Metastatic Breast Cancer
This study is being done to find the effect of Stereotactic body radiation therapy (SBRT) in combination with Ixabepilone for women with triple negative metastatic breast cancer.
- Trial name
- NCT01818999
- Testing
- IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Metastatic Breast Cancer in the Liver
Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy
This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.
- Trial name
- Castle06(BC) (NCT05303038)
- Testing
- Cryoablation Combined with Tirelizumab and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Fudan University
Triple Negative Breast Neoplasms
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
This is a multicenter, open-label, randomized phase II trial evaluating the efficacy and safety of sacituzumab govitecan plus toripalimab versus toripalimab plus nab-paclitaxel in patients with previously untreated, unresectable…
- Trial name
- NCT07040644
- Testing
- Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Axillary Nodal Burden in HER2+ and TNBC
This study aimed to evaluated rates of pathologic axillary nodal metastasis in patients with with early-stage HER2-positive BC or TNBC who had clinically node-negative status on preoperative ultrasonography and underwent upfront…
- Trial name
- NCT07211451
- Testing
- Breast conserving surgery with axillary surgery
- Where
- South Korea
- Volunteers
- 1,571 people
- Sponsor
- Gangnam Severance Hospital